Dr Reddys Labs - RDY STOCK NEWS

Dr. Reddy’s Laboratories Ltd. has announced the re-launch of its OTC Naproxen Sodium Tablets USP, 220 mg in the U.S., approved by the FDA. This product is a store-brand equivalent of Aleve® and serves as a pain reliever and fever reducer. CEO Marc Kikuchi highlighted its significance in the company's Pain/Analgesics portfolio, emphasizing the robust supply chain for consistent product availability. Naproxen Sodium had U.S. retail sales of around $316 million as of July 2021, and the tablets will come in various pack sizes for consumer convenience.

Dr. Reddy's Laboratories has filed its Annual Report on Form 20-F with the SEC for the fiscal year ending March 31, 2021. The report includes consolidated financial statements prepared in accordance with IFRS. Shareholders can access the report online at www.drreddys.com or request a hard copy. The company operates through three key divisions, focusing on affordable and innovative pharmaceuticals in various therapeutic areas across global markets including the USA, India, and Europe.

Dr. Reddy's Laboratories Ltd. has launched Icosapent Ethyl Capsules (1 gram), approved by the U.S. FDA, indicated for lowering triglyceride levels in patients with severe hypertriglyceridemia (≥ 500 mg/dL). The product, available in bottles of 120 capsules, is not approved for reducing cardiovascular risks associated with elevated triglyceride levels. Important safety information includes potential risks of heart arrhythmias, allergic reactions, and bleeding, particularly in patients on anticoagulants. Full prescribing information can be accessed here.

Global Response Aid (GRA) announced significant global sales of its anti-viral drug Avigan®/Reeqonus™ for treating COVID-19, totaling $33 million in revenue. The company has partnered with Dr. Reddy's (NYSE: RDY) and initiated a global Phase 3 clinical trial, reporting a positive interim outlook. Countries including India, Thailand, and Malaysia have approved Avigan® for treatment, with a notable order of over 65 million tablets from the Japanese government. GRA's CEO expressed optimism about Avigan®'s role in combating the pandemic.

Dr. Reddy’s Laboratories Ltd. has launched Albendazole Tablets, USP, a generic equivalent of Albenza Tablets, approved by the USFDA. This product comes in 200 mg tablets and is available in bottle sizes of two. The Albenza brand, whose U.S. sales reached approximately $27 million over the last twelve months, is owned by Glaxosmithkline. The launch aims to expand Dr. Reddy’s portfolio in the generics market, enhancing accessibility to affordable medications.

Dr. Reddy's Laboratories (NYSE: RDY) has received approval from the Drug Controller General of India (DCGI) to import the Sputnik V vaccine for emergency use in India. This follows their collaboration with the Russian Direct Investment Fund (RDIF) since September 2020 to conduct clinical trials. Dr. Reddy's is now contributing to India's vaccination efforts amid rising COVID-19 cases. Sputnik V, which boasts an efficacy rate of 91.6%, has been approved in 60 countries globally and ranks second in vaccine approvals worldwide.

Dr. Reddy’s Laboratories has launched a generic version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, approved by the U.S. FDA. This product is a therapeutic equivalent to Kuvan® and reflects the company's commitment to providing affordable medications. Available in 30-count cartons, it aims to expand Dr. Reddy’s portfolio in rare disease treatments. The CEO emphasizes the importance of this launch in enhancing patient access to essential medications.

Dr. Reddy’s Laboratories announced the launch of Lansoprazole DR Orally Disintegrating Tablets, a generic version of Prevacid SoluTab, in 15 mg and 30 mg dosages. This product received approval from the U.S. FDA and targets a market that generated approximately $87 million in U.S. sales over the past year. The tablets are available in unit-dose packages of 100. Dr. Reddy’s is committed to providing affordable medicines globally, with major therapeutic focuses including gastrointestinal and oncology.

Dr. Reddy’s Laboratories has launched Fluphenazine Hydrochloride Tablets, USP, a generic version of Prolixin Tablets, approved by the U.S. FDA. Available in 1 mg, 2.5 mg, 5 mg, and 10 mg doses, these tablets are expected to cater to a market with U.S. sales of approximately $134 million for the brand and generic within the last year. The launch is part of Dr. Reddy’s commitment to providing affordable medicines. The drug carries a warning regarding increased mortality risk in elderly patients with dementia-related psychosis.